Skip to main content
China Resources Pharmaceutical Group Limited logo

China Resources Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 3320 ISIN · HK0000311099 LEI · 3003004H1KDKMJ8JD874 HKEX Manufacturing
Open in API
Filings indexed 813 across all filing types
Latest filing 2025-08-26 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 3320

About China Resources Pharmaceutical Group Limited

http://www.crpharm.com

China Resources Pharmaceutical Group Limited operates an integrated pharmaceutical value chain encompassing research and development, manufacturing, distribution, and retail of medicines and healthcare products. As an investment holding company, it manages a diverse portfolio focused primarily on the domestic market. Its manufacturing capabilities span multiple therapeutic areas, including chemical drugs, biological drugs, natural medicine, and traditional Chinese medicine. The group leverages its extensive distribution network and retail operations to ensure broad market coverage across China.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 85% confidence The document is an official announcement listing the company’s board of directors, their roles, and committee memberships, dated and signed. This constitutes a Board/Management Information update rather than a full report or regulatory filing. Therefore it fits category MANG (Board/Management Information).
2025-08-26 English
CHANGE OF EXECUTIVE DIRECTORS&#x3b; CHANGE IN COMPOSITION OF BOARD COMMITTEES&#x3b; AND APPOINTMENT OF PRESIDENT
Board/Management Information Classification · 90% confidence The document is an announcement regarding the resignation and appointment of executive directors and changes in board committees, detailing board composition changes and new appointments. This falls under Board/Management Information.
2025-08-26 English
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF CR DOUBLE-CRANE FOR THE SIX MONTHS ENDED 30 JUNE 2025
Earnings Release Classification · 85% confidence The document is a Hong Kong listing announcement summarizing unaudited interim results for the six months ended 30 June 2025. It provides key financial highlights (revenue, net profit, earnings per share, dividend proposal) but refers readers to the full interim report published on the Shanghai Stock Exchange website for details. It is not the full interim report itself (not comprehensive financial statements), nor is it simply a notice of publication devoid of numbers. It matches an Earnings Release: an initial announcement of periodical financial results (key highlights only). H2 2025
2025-08-22 English
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF CR BOYA BIO-PHARMACEUTICAL FOR THE SIX MONTHS ENDED 30 JUNE 2025
Earnings Release Classification · 85% confidence The document is an announcement by China Resources Pharmaceutical Group summarizing unaudited interim results for its subsidiary CR Boya Bio-pharmaceutical for the six months ended 30 June 2025. It provides key financial highlights only (revenue, net profit, basic EPS, etc.) and refers readers to the full interim report published elsewhere. This matches the definition of an Earnings Release (initial announcement of quarterly/periodical financial results with key highlights only) rather than a full Interim Report (which would include detailed financial statements) or a simple report publication notice. Therefore, the correct classification is ER (Earnings Release). H1 2025
2025-08-22 English
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF DONG-E-E-JIAO FOR THE SIX MONTHS ENDED 30 JUNE 2025
Earnings Release Classification · 92% confidence The document is an announcement by China Resources Pharmaceutical Group Limited summarizing key unaudited financial results of its subsidiary Dong-E-E-Jiao for the six months ended 30 June 2025. It provides headline metrics (assets, revenue, profit, EPS) and dividend proposals but refers to the full interim report published elsewhere. This fits the definition of an Earnings Release (initial announcement of periodical financial results with key highlights), rather than a full Interim Report or Annual Report. Therefore, it should be classified as ER. H2 2025
2025-08-21 English
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF JIANGZHONG PHARMACEUTICAL FOR THE SIX MONTHS ENDED 30 JUNE 2025
Earnings Release Classification · 80% confidence The document is an announcement of the unaudited financial results for the six months ended 30 June 2025, providing key financial metrics (revenue, net profit, EPS, etc.) and a brief narrative summary. It is not the full interim report itself but rather the initial announcement of periodical financial results. This aligns with the definition of an Earnings Release (ER). H2 2025
2025-08-21 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.